Sept. 27 (Bloomberg) -- Pfizer Inc., struggling to revive its stock, is targeting the projected $12.6 billion rheumatoid arthritis market with an unlikely product: the company's newest AIDS treatment.
Read More...
[Source: Yahoo! News Search Results for liver disease help]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment